ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	JPRN
Last refreshed on:	17 October 2023
Main ID:	JPRN-UMIN000016101
Date of registration:	02/01/2015
Prospective Registration:	Yes
Primary sponsor:	National Center for Global Health and Medicine
Public title:	Investigation on the efficacy and safety of favipiravir in patients who are infected or strongly suspected of being infected with Ebola virus
Scientific title:	Investigation on the efficacy and safety of favipiravir in patients who are infected or strongly suspected of being infected with Ebola virus - Therapeutic effect of favipiravir on Ebola virus disease
Date of first enrolment:	2015/01/19
Target sample size:	5
Recruitment status:	Complete: follow-up complete
URL:	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018699
Study type:	Interventional
Study design:	Single arm Non-randomized
Phase:	Not selected

Countries of recruitment
Japan

Contacts

Name:	Yasuyuki Kato
Address:	1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan Japan
Telephone:	03-3202-7181
Email:	ykato@hosp.ncgm.go.jp
Affiliation:	National Center for Global Health and Medicine Division of Preparedness and Emerging Infections, Disease Control and Prevention Center

Name:	Yasuyuki Kato
Address:	1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan Japan
Telephone:	03-3202-7181
Email:	ykato@hosp.ncgm.go.jp
Affiliation:	National Center for Global Health and Medicine Division of Preparedness and Emerging Infections, Disease Control and Prevention Center

Key inclusion & exclusion criteria

Inclusion criteria:
Exclusion criteria: Patient who was considered as inadequate for this study by the Case Management Committee.

Age minimum: Not applicable
Age maximum: Not applicable
Gender: Male and Female

Health Condition(s) or Problem(s) studied

Ebola virus disease

Intervention(s)

Favipiravir is given for 14 days after study initiation.

Primary Outcome(s)

Patient survival at the end of study or at discontinuation

Secondary Outcome(s)

Secondary ID(s)

Source(s) of Monetary Support

Ministry of Health, Labour and Welfare, Japan

Secondary Sponsor(s)

Ethics review

Status: YES
Approval date:
Contact:

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.